AnPac Bio-Medical Science Co. Ltd. (ANPC)
Stock Price:
$3.21 USD
-0.15 (-4.46%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $3.27 +0.06 (1.87%) Oct 30, 6:25 PM
Key Info
| Market Cap |
26.77M |
| Revenue (ttm) |
1.55M |
| Net Income (ttm) |
-14.44M |
| Shares Out |
8.34M |
| EPS (ttm) |
-1.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$3.21 |
| Previous Close |
$3.36 |
| Change ($) |
-0.15 |
| Change (%) |
-4.46% |
| Day's Open |
3.38 |
| Day's Range |
3.18 - 3.46 |
| Day's Volume |
18,289 |
| 52-Week Range |
3.15 - 12.18 |
More Stats
| Market Cap |
26.77M |
| Enterprise Value |
31.40M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
8.34M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.62 |
| FCF / Share |
-0.82 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
8,023 |
| Short Ratio |
0.33 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
17.28 |
| PB Ratio |
10.91 |
| Revenue |
1.55M |
| Operating Income |
-12.73M |
| Net Income |
-14.44M |
| Free Cash Flow |
-7.34M |
| Net Cash |
-4.63M |
| Net Cash / Share |
-0.56 |
| Gross Margin |
44.24% |
| Operating Margin |
-821.41% |
| Profit Margin |
-931.90% |
| FCF Margin |
-473.86% |
| ROA |
-105.30% |
| ROE |
n/a |
| ROIC |
5,136.30% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.50*
(289.41% upside)
Low
7.00
Current: $3.21
High
18.00
Target: 12.50
*Average 12-month USD price target from 2 stock analysts.
Financial Performance
Financial numbers in millions CNY.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 10.85 | 10.25 | 5.69 |
| Revenue Growth | 5.8% | 80.27% | - |
| Gross Profit | 4.80 | 4.58 | 1.73 |
| Operating Income | -89.08 | -43.61 | -40.92 |
| Net Income | -101 | -42.06 | -39.08 |
| Shares Outstanding | 8.94 | 8.52 | 7.94 |
| Earnings Per Share | -11.31 | -4.93 | -4.92 |
| Operating Cash Flow | -48.60 | -31.15 | -21.64 |
| Capital Expenditures | -2.79 | 2.84 | -2.60 |
| Free Cash Flow | -51.39 | -28.31 | -24.25 |
| Cash & Equivalents | 6.13 | 12.89 | 11.41 |
| Total Debt | 38.57 | 25.96 | 12.50 |
| Net Cash / Debt | -32.44 | -13.07 | -1.09 |
| Assets | 52.98 | 52.76 | 60.15 |
| Liabilities | 68.91 | 75.16 | 50.65 |
| Book Value | -15.97 | -22.39 | 9.56 |
Numbers in millions CNY, except per-share numbers.
Company Details
| Full Name |
AnPac Bio-Medical Science Co. Ltd. |
| Country |
China |
| Employees |
111 |
| CEO |
Chang Yu |
Stock Information
| Ticker Symbol |
ANPC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ANPC |
| IPO Date |
January 30, 2020 |
Description
Anpac Bio-Medical Science Company, a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.